SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as retail investors rally behind heavy institutional buying, with firms like Morgan Stanley significantly increasing their positions ahead of a busy schedule of oncology conferences. The market is hyper-focused on the company's REGAL clinical trial reaching 78 of 80 required events, fueling community speculation about a looming data readout and potential M&A activity.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

Technip Energies is capturing market attention as the company gains momentum with major engineering contracts and positive operational news, fueling community excitement about its growth in the U.S. manufacturing and energy infrastructure sector. Investors are closely monitoring the stock as sentiment shifts, with many actively discussing potential setups, analyst target revisions, and the company's positioning within the broader renewable energy and power grid evolution.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is currently trending due to a combination of heavy institutional scrutiny, ongoing AI monetization concerns following an analyst downgrade, and community debate over the company's valuation as a 'cash machine' versus its growth prospects. Investors are actively discussing the stock's potential as a long-term value play supported by a massive buyback program, while others fear that AI agents may disrupt its traditional subscription-based business model.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike Inc is experiencing intense selling pressure, with the stock trading at multi-year lows as market participants express deep skepticism over its turnaround efforts, leadership, and loss of market share. While some retail traders are betting on a recovery fueled by upcoming catalysts like the World Cup and potential tariff relief, many others are aggressively shorting the name, citing concerns over inventory, declining demand, and a perceived loss of brand resonance.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors react to a new executive order aimed at fast-tracking psychedelic drug research and streamlining regulatory reviews through priority vouchers. The community is actively discussing the stock's role as a potential first-mover in the treatment-resistant depression market, with many focused on the upcoming release of pivotal trial data and speculation regarding long-term acquisition interest from major pharmaceutical players.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is facing significant volatility following a wider-than-expected net loss and missed revenue targets, though the companys raised forward guidance and strategic shift toward branded GLP-1 distributions have sparked debate. Community discourse remains deeply divided between those viewing the pullback as a buying opportunity based on long-term growth in peptides and personalized healthcare, and skeptics who remain concerned about margin compression and the sustainability of the company's valuation.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors react to the launch of 'Ford Energy,' a new subsidiary focusing on battery energy-storage systems for data centers and industrial customers to capture AI-driven power demand. The community is actively debating whether this strategic pivot marks a valuation re-rating that transforms the legacy automaker into a high-growth AI infrastructure play.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as the community actively debates its positioning in the Chinese AI and cloud infrastructure sector following mixed Q1 earnings and ongoing interest in its robotaxi and agentic AI initiatives. While some investors remain cautious about legacy ad revenue declines and geopolitical volatility, bullish sentiment persists around the company's long-term potential to capitalize on domestic AI demand and potential value realization from its subsidiary spinoffs.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending due to reports that NextEra Energy is in advanced talks to acquire the utility in a deal valued at approximately $66 billion, a move driven by the massive surge in electricity demand from AI and data center expansion. The community is actively debating the potential regulatory and antitrust hurdles for such a large-scale merger, while also discussing the impact on dividend consistency and the strategic fit of integrating Dominion's infrastructure into NextEra's portfolio.

LiveRamp Holdings, Inc. is a global technology company, which engages in the provision of a data collaboration platform in consumer privacy, data ethics, and foundational identity. The company was founded in 1969 and is headquartered in San Francisco, CA.

LiveRamp Holdings Inc

LiveRamp is trending following an acquisition agreement by Publicis, a move that the investment community is analyzing as a significant shift toward agency-owned data infrastructure. While some investors are debating the deal's valuation and the resulting arbitrage opportunities, many are actively discussing the broader implications for the ad-tech landscape and the impact on long-term shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The data were presented at the American Urological Association (AUA) 2026 Annual Meeting.</li><li>Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug.</li><li>If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.</li></ul> Shares of Candel Therapeutics Inc. (CADL) rose 3% in after-hours trading on Friday following the release of extended follow-up data from its pivotal late-stage trial of CAN-2409 in intermediate- to high-risk localized prostate cancer.The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo in the intention-to-treat population. In the intermediate-risk subgroup — which made up 85% of the 745-patient trial — the benefit was even stronger, with a 41% reduction in risk of recurrence, along with notable improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, the firm said.The data, which reinforces the potential of the drug to reduce the risk of tumor recurrence, were presented at the American Urological Association (AUA) 2026 Annual Meeting.<h2 class="st-heading-2">Plan Ahead</h2>Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug. If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.<h2 class="st-heading-2">What Did Phase 3 Results Show?</h2>In December 2024, Candel reported positive late-stage results for CAN-2409. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.The drug has already received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration.<h2 class="st-heading-2">How Did CADL Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has risen 72% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dal-m-amzn-v-unh-in-focus-as-berkshire-rejigs-portfolio/cZXmfX1Rekg">DAL, M, AMZN, V, And UNH Stocks In Focus As Berkshire Rejigs Portfolio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data  

The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo. 

Equity

<ul class="summary-bullets"><li>Leerink said recent stock weakness tied to a competitor downgrade and board departures has created a buying opportunity ahead of key pancreatic cancer data expected later this year.</li><li>Mizuho raised its price target for TNGX to $30 from $20 and maintained an ‘Outperform’ rating, citing stronger front-line pancreatic cancer revenue expectations.</li><li>Wedbush raised its price target on Tango Therapeutics to $33 from $19 and maintained an ‘Outperform’ rating, citing recent financing activity and progress in vopimetostat development.</li></ul>Shares of Tango Therapeutics Inc. (TNGX) lost more than a fifth of their value on Friday after the company reported revenue of $0 in the first quarter, missing Wall Street expectations.Despite the first-quarter (Q1) miss, analysts at Leerink nearly doubled their price target for TNGX stock on Friday, according to TheFly.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/TNGX">Tango Therapeutics shares</a> were headed for their worst single-day fall in more than 19 months.<h2 class="st-heading-2">Leerink, Mizuho, Wedbush Turn Bullish On TNGX</h2>Leerink raised its price target on Tango Therapeutics to $55 from $28, implying an upside potential of 184% from current levels, while maintaining its ‘Outperform’ rating after the company’s Q1 results and pipeline update.The firm said recent stock weakness tied to a competitor downgrade and board departures has created a buying opportunity ahead of key pancreatic cancer data expected later this year.Leerink also backed Tango’s decision to prioritize first-line pancreatic cancer studies combining vopimetostat with RAS(ON) inhibitors over a standalone second-line trial.Analysts at Mizuho raised their price target on Tango Therapeutics to $30 from $20, while keeping an ‘Outperform’ rating. The firm cited increased front-line pancreatic ductal adenocarcinoma revenue assumptions for the target boost.Wedbush raised its price target on Tango Therapeutics to $33 from $19 and maintained an ‘Outperform’ rating. The analysts cited the company’s recent financing activity and progress in the development of vopimetostat.However, analysts at Piper Sandler downgraded TNGX stock to ‘Neutral’ from ‘Overweight’, but hiked the price target to $24 from $16. The firm stated that it has become less confident in vopimetostat following the company’s shift away from its previously disclosed monotherapy strategy.<h2 class="st-heading-2">TNGX Q1 At A Glance</h2>Tango Therapeutics reported adjusted loss per share of $0.32 in Q1, compared to a loss of $0.36 per share during the same period a year ago. Revenue was nil for the quarter, compared with $5.4 million in the year-ago period.Wall Street expected Tango Therapeutics to report a loss of $0.31 per share on revenue of $0.58 million, according to Fiscal.ai data.The company stated that it had recognized all remaining deferred revenue tied to upfront and research option-extension payments under its Gilead collaboration in fiscal year 2025, after the agreement was terminated and all research activities had concluded.<h2 class="st-heading-2">TNGX Provides Update On Upcoming Milestones</h2>The company expects to report initial Phase 1/2 safety and efficacy data in 2026 for vopimetostat combination trials with daraxonrasib and Revolution Medicines’ zoldonrasib.It also plans to provide a lung cancer update from its vopimetostat monotherapy study this year, along with the release of early Phase 1/2 data from the TNG456 monotherapy trial this year.Additionally, the company aims to begin a Phase 1/2 combination study of vopimetostat and Erasca’s ERAS-0015 in the second half of 2026.<h2 class="st-heading-2">How Did Retail Traders React To TNGX?</h2>Retail sentiment on Stocktwits around Tango Therapeutics trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/TNGX">TNGX stock</a> is up 120% year-to-date and 1,182% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 34% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 68%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apollo-torsten-slok-inflation-very-serious-fed-rate-hike-kevin-warsh-powell/cZXmcm4RekG">Apollo’s Torsten Slok Warns Inflation Has Become A ‘Very Serious’ Problem — Says Markets Now Expect Fed Rate Hikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tango Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Shares of Tango Therapeutics Inc. (TNGX) lost more than a fifth of their value on Friday after the company reported revenue of $0 in the first quarter, missing Wall Street expectations.

Leerink raised its price target on Tango Therapeutics to $55 from $28, implying an upside potential of 184% from current levels, while maintaining its ‘Outperform’ rating.

IWM, BE, STRL, FN: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 ETF (Symbol: IWM) where we have detected an...

<ul class="summary-bullets"><li>The hold follows the company’s earlier voluntary pause in late February 2026, triggered by reversible cardiac observations seen at supratherapeutic doses in a healthy volunteer study.</li><li>Aardvark now plans to unblind the clinical data accumulated to date for ARD-101 to assess the full efficacy and safety profile.</li><li>The company also said that it will continue to engage with the FDA on the path forward for its lead candidate.</li></ul>Aardvark Therapeutics (AARD) shares tumbled 17% in after-hours trading on Thursday, after the company disclosed that the U.S. Food and Drug Administration has placed a full clinical hold on its lead candidate ARD-101.Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in Prader-Willi Syndrome patients and the associated open-label extension (OLE) study. The hold follows the company’s earlier voluntary pause in late February 2026, triggered by reversible cardiac observations seen at supratherapeutic doses in a healthy volunteer study.<h2 class="st-heading-2">AARD’s Next Steps</h2>“We are continuing to work collaboratively with the agency to comprehensively evaluate the data and determine the best path forward for ARD-101,” said CEO Tien Lee while reiterating commitment to patient safety.In parallel with FDA discussions, Aardvark plans to unblind the clinical data accumulated to date for ARD-101 to assess the full efficacy and safety profile and inform next steps. As of late February, 87 patients have been dosed in the two trials, the company said.ARD-101 is an oral small-molecule aimed at addressing hyperphagia—the insatiable hunger characteristic of PWS, a rare genetic disorder. This latest development adds to the uncertainty around the ARD-101 program, which had already seen its late-stage topline results delayed. The company was previously expecting to release topline data in the third quarter of 2026, but scrapped that timeline after the voluntary pause imposed in February. No fresh timeline has been issued so far.The company reported a solid cash position of $91.2 million as of March 31, 2026, which it believes is sufficient to fund operations into mid-2027.<h2 class="st-heading-2">How Did AARD Retail Traders React?</h2>On Stocktwits, retail sentiment around AARD stock stayed within the ‘neutral’ territory while message volume remained at ‘high’ levels.According to data from Koyfin, eight of the 12 analysts covering AARD rate it ‘Buy’ while four rate it ‘Hold.’ The 12-month average price target on the stock is $16.70, representing a potential upside of about 148%.Earlier this week, Bank of America lowered its price target on AARD to $18 from $20 while retaining its ‘Buy’ rating on the stock after the firm released its first quarter report, wherein it said that it will provide further guidance on its ARD-101 and ARD-201 programs in the second quarter. The company placed a voluntary pause on ARD-201 in March, as it is a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor being studied for weight loss and weight regain prevention.<a href="https://stocktwits.com/symbol/AARD">AARD stock</a> has fallen 23% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pzza-stock-rallies-after-hours-on-report-of-largest-us-franchisee-joining-1.5billion-buyout-push/cZXS5XnReSK">PZZA Stock Rallies After Hours On Report Of Largest US Franchisee Joining $1.5B Buyout Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program

Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in PWS patients and the associated open-label extension (OLE) study.

<ul class="summary-bullets"><li>REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, raising cash concerns.</li><li>Cash, cash equivalents, and marketable securities stood at $150.5 million at Q1-end, which the firm expects to be sufficient to fund its operations into early 2027.</li><li>Both Q1 revenue and earnings fell short of Wall Street expectations on Thursday.</li></ul>Shares of REGENXBIO Inc. (RGNX) dropped 37% on Thursday after the company reported disappointing first-quarter 2026 (Q1) financial results that overshadowed positive pivotal late-stage trial data for its lead Duchenne muscular dystrophy candidate RGX-202.The stock is on track for its worst day ever, if losses hold.<h2 class="st-heading-2">RGNX’s Q1 Earnings</h2>The company reported that revenue for the three months ended March 31 plunged to $6.4 million from $89.0 million a year earlier, and below an analyst estimate of $25.25 million. The steep decline was driven by the absence of a $70 million upfront license payment recognized in Q1 2025 under the Nippon Shinyaku collaboration and lower royalties from Novartis’ ZOLGENSMA after U.S. patent expiration in January 2026.REGENXBIO swung to a net loss of $90.1 million, or $1.72 per share, compared with net income of $6.1 million, or $0.12 per share, in the prior-year quarter. Wall Street, on average, had estimated a loss of only $1.3/ share.Cash, cash equivalents, and marketable securities stood at $150.5 million at quarter-end, which the firm expects to be sufficient to fund its operations into early 2027.<h2 class="st-heading-2">DMD Trial Readout</h2>In a separate announcement, REGENXBIO reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder characterized by muscle degeneration and weakness, primarily affecting young boys.The study met its main goal. Ninety-three percent of patients produced high levels of the needed muscle protein after 12 weeks, averaging 71%.One-year data from some patients showed meaningful improvements in movement and muscle function compared to untreated boys. The treatment was generally safe, with two serious side effects that resolved, Regenxbio said.The results support plans for an accelerated approval filing and subsequent launch in 2027, the firm said. REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, which could add uncertainty to the timeline, though the company remains optimistic and plans further FDA discussions.<h2 class="st-heading-2"> How Did RGNX Retail Traders React?</h2>On Stocktwits, retail sentiment around RGNX stock increased from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed hopes for the stock recovering after the “overreaction.” The user sees the company’s market cap touching $1 billion in time, up from its current near $330 million market cap now.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/653352403</stembedurl>Another user expressed hopes for Novartis buying the company.<stembedurl>https://www.stocktwits.com/murphylaw/message/653377645</stembedurl>Another user highlighted that the company doesn’t seem to have enough cash to conduct another trial if the FDA insists.<stembedurl>https://www.stocktwits.com/Find_the_Cure/message/653359896</stembedurl><a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has fallen by about 23% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ivvd-stock-fell-today-but-this-analyst-sees-730-percent-upside/cZX1UFNReSa">IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regenxbio logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success  

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.

The Battle of iShares ETFs: Should You Buy the S&P 500 ETF or Russell 2000?

Key PointsiShares Core S&P 500 ETF provides lower-cost exposure to large-cap equities with an expense ratio of 0.03% compared to 0.19% for iShares Russell 2000 ETF...

<ul class="summary-bullets"><li>Operating expenses fell in Q1 after Omeros sold its experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.</li><li>Omeros is now awaiting a European Medicines Agency decision on the Yartemlea marketing authorization application.</li></ul>Omeros Corporation (OMER) shares rose more than 4% in after-hours trading on Wednesday after the company reported its first quarter of commercial revenue from the U.S. launch of YARTEMLEA for transplant-associated thrombotic microangiopathy (TA-TMA).Omeros posted first-quarter net product sales of $9.9 million, compared with zero in the year-ago period when the drug was not yet approved or launched, and above an estimated $4.11 million. Adjusted net loss narrowed to $0.24 per share, compared to a loss of $0.58 in the corresponding quarter of last year, and below a loss of $0.29 expected by Wall Street analysts.The company ended the quarter with $135.3 million in cash, cash equivalents, and short-term investments. Operating expenses fell sharply to $27.3 million from $35.0 million a year earlier, driven mainly by lower research and development spending after the earlier sale of the firm’s experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.“The launch of YARTEMLEA has changed the trajectory of Omeros, both operationally and financially. We are seeing strong early adoption across transplant centers, expanding formulary access, favorable reimbursement support, and growing physician experience with the first and only approved treatment for TA-TMA,” CEO Gregory A. Demopulos said. Omeros launched Yartemlea in the U.S. in January for TA-TMA, or a severe, often fatal complication of bone marrow transplantation.Omeros also noted several upcoming catalysts, including a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026. The company continues to advance its broader pipeline, including OMS527 for cocaine use disorder, and T-CAT programs targeting multidrug-resistant pathogens.<h2 class="st-heading-2">How Did OMER Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user opined that the after-hours price action does not justify the company’s “great” earnings call.<stembedurl>https://www.stocktwits.com/jmmoore4/message/653300780</stembedurl>Another user said that they see the stock climbing to $20 as the EMA decision nears and further to $100 in time.<stembedurl>https://www.stocktwits.com/MayorofMNKD/message/653296248</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has more than tripled in value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/envx-stock-tumbles-after-hours-on-smartphone-battery-qualification-timeline-concerns/cZXLUN5ReKA">ENVX Tumbles After Hours On Smartphone Battery Qualification Timeline Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations  

Yartemlea net sales in Q1 came in at $9.9 million, higher than the $4.1 million expected by Wall Street. 

<ul class="summary-bullets"><li>Talluri acknowledged that the qualification process has taken longer than expected.</li><li>He further noted encouraging results in energy density, fast charging, and safety, with longer-term cycle-life testing still ongoing.</li><li>The company provided second-quarter guidance of $8.0 million to $9.0 million in revenue and adjusted net loss per share of $0.13 to $0.17.</li></ul>Shares of Enovix Corporation (ENVX) fell 12% after hours on Wednesday, as investors appeared disappointed by the firm’s smartphone battery qualification timelines despite first-quarter earnings beating Wall Street expectations.The silicon battery cell maker’s CEO Raj Talluri said smartphones remain the company’s top priority as it works to finish qualification with its lead customer and prepare for commercial production in the demanding consumer electronics market.The company has reached a key milestone by agreeing with its lead smartphone customer on a new testing framework designed specifically for its silicon batteries. Talluri added that the second smartphone customer also agrees that the old industry testing standard is not suitable for silicon technology, and the two sides are discussing a replacement framework.Talluri acknowledged that the qualification process has taken longer than expected. He further noted encouraging results in energy density, fast charging, and safety, with longer-term cycle-life testing still ongoing. Beyond smartphones, the company’s defense business continues to show strong commercial momentum, and its battery for smart eyewear has entered early production, Talluri said.<h2 class="st-heading-2">ENVX Q1 Earnings</h2>On Wednesday, Enovix reported first-quarter 2026 revenue of $7.6 million, a 49% increase from $5.1 million in the year-ago period, driven by higher shipments in defense and industrial markets.Adjusted net loss was $0.14 per share in the quarter versus $0.13 per share in the prior-year quarter and below an estimated loss of $0.19. Enovix ended the quarter with $582.7 million in cash, cash equivalents, and marketable securities.<h2 class="st-heading-2">Looking Ahead</h2>The company provided second-quarter guidance of $8.0 million to $9.0 million in revenue, in line with an expected $8.57 million, and adjusted net loss per share of $0.13 to $0.17, lower than the loss of $0.20 expected by Wall Street. Capital expenditures are expected to range between $9.0 million and $13.0 million, the firm said.<h2 class="st-heading-2">How Did ENVX Retail Traders React?</h2>On Stocktwits, retail sentiment around ENVX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed disappointment over the delays in the smartphone testing segment but highlighted that the company also made “some real progress.”<stembedurl>https://www.stocktwits.com/ointhebay/message/653292246</stembedurl>Another user highlighted that the company is catering to multiple industries instead of relying on just the smartphone business.<stembedurl>https://www.stocktwits.com/Stingraystev/message/653292506</stembedurl><a href="https://stocktwits.com/symbol/ENVX">ENVX stock</a> has fallen 8% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-stock-draws-attention-as-culper-research-takes-short-position-over-china-ties/cZXLrSBReKF">Nvidia Stock Draws Attention As Culper Research Takes Short Position Over China Ties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Enovix Corporation.

ENVX Tumbles After Hours On Smartphone Battery Qualification Timeline Concerns

The battery cell maker’s CEO Raj Talluri said smartphones remain the company’s top priority.

<ul class="summary-bullets"><li>Integrated memory revenue rose 53% year-on-year to $308 million in H1 FY2026, accounting for roughly 45% of Penguin Solutions’ total revenue of $686 million during the period.</li><li>Penguin Solutions stated that the next phase of AI will focus on inference rather than training.</li><li>The company said its products are designed to help customers optimize token economics and scale inference workloads efficiently.</li></ul>Shares of Penguin Solutions Inc. (PENG) were up more than 20% in Wednesday’s pre-market trade, on track for their best single-day gains in about 22 months.The company stated on Tuesday that its AI-driven business accounted for more than 60% of total sales during the first half of fiscal year 2026, up more than 50% year over year.<h2 class="st-heading-2">PENG Banks On Agentic AI Boom</h2>Penguin Solutions stated that the next phase of AI will focus on inference rather than training. The company said its products are designed to help customers optimize token economics and scale inference workloads efficiently.Penguin stated that inference aligns with its expertise in building customized high-performance AI infrastructure tailored to specific customer workloads.Integrated memory revenue rose 53% year-on-year to $308 million in H1 FY2026, accounting for roughly 45% of Penguin Solutions’ total revenue of $686 million during the period.<h2 class="st-heading-2">Rosenblatt Says PENG’s Expansion Plans Are Impressive</h2>According to TheFly, Rosenblatt analysts said that Penguin Solutions CEO Kash Shaikh’s strategy to build on the company’s more than 40 years of memory-subsystem expertise is compelling.The analysts added that the company is combining that foundation with AI software and services to deliver a full-stack platform solution.Rosenblatt raised its price target for PENG stock to $54 from $32, while keeping a ‘Buy’ rating. The firm noted that the higher price target reflects rising demand for optimized memory subsystems in the AI market, as well as faster corporate adoption of internal AI systems driven by agentic AI.<h2 class="st-heading-2">PENG Says AI Moving From Pilots To Deployment</h2>According to the firm, AI is now moving beyond pilots to full-on-premises deployments, and demand is broadening from hyperscalers to enterprises and sovereign customers. The demand for memory is increasing as AI workflows move into production at scale.The company also highlighted that its integrated memory modules are built into the infrastructure platforms of industry leaders, which include Alphabet Inc.’s (GOOG, GOOGL) Google, Intel Corp. (INTC), and Juniper Networks, among others.<h2 class="st-heading-2">What Does PENG Do?</h2>Penguin Solutions is a Fremont, California-based company that provides memory and AI infrastructure designed to support enterprises, sovereign AI projects, and neocloud providers.The company offers a full-stack platform comprising hardware and software solutions to help customers deploy and scale AI workloads while optimizing their total cost of ownership.<h2 class="st-heading-2">How Did Retail Traders React To PENG?</h2>Retail sentiment on Stocktwits around Penguin Solutions trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/PENG">PENG stock</a> is up 126% year-to-date and 133% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 36% over the past 12 months, while the iShares Core S&amp;P Small-Cap ETF (IJR) is up 26%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/googl-spacex-reportedly-in-talks-to-launch-data-centers-in-orbit-spacex-ipo/cZXXjlVReio">Google, SpaceX Reportedly In Talks To Launch Data Centers In Orbit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Penguin Solutions logo is seen displayed on a smartphone screen

PENG Stock Heads For Best Single-Day Gains In 22 Months — Penguin Says AI-Driven Business Now Accounts For 60% Of H1 Revenue

Penguin Solutions reported that its AI-driven business revenue soared by more than 50% year over year in the first half of fiscal year 2026.

<ul class="summary-bullets"><li>The new results from the ongoing ENABLE trial, based on a December 22, 2025, data cutoff, showed encouraging efficacy and a favorable safety profile for ELVN-001 &nbsp;in heavily pretreated patients with chronic-phase chronic myeloid leukemia.</li><li>Enliven is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026.</li><li>Separately, Guggenheim Securities initiated coverage of Enliven late Monday with a ‘Buy’ rating and an $80 price target.</li></ul> Shares of Enliven Therapeutics (ELVN) jumped 7% on Tuesday after the company announced that it will present positive data on its lead candidate at an upcoming conference on the heels of a Wall Street push for its experimental cancer drug.Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm next month.<h2 class="st-heading-2">Key Trial Data</h2>The new results from the ongoing ENABLE trial, based on a December 22, 2025, data cutoff, showed encouraging efficacy and a favorable safety profile for ELVN-001 &nbsp;in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CML). Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.As of the cutoff, 141 patients had been enrolled across dose levels, with 76% remaining on treatment and a median treatment duration of 31.7 weeks, the company said.“As we treat more patients and extend follow-up, ELVN-001 continues to demonstrate robust anti-CML activity in a heavily pretreated patient population,” said Helen Collins, chief medical officer of Enliven. “These results are consistent with our earlier findings demonstrating a favorable safety and tolerability profile, reinforcing ELVN-001’s highly selective design.”The oral presentation is scheduled for June 11, 2026. Enliven, a clinical-stage biopharmaceutical company focused on small molecule therapeutics, is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026.<h2 class="st-heading-2">Wall Street Push</h2>Separately, Guggenheim Securities initiated coverage of Enliven late Monday with a ‘Buy’ rating and an $80 price target.The firm described ELVN-001 as a “potential best-in-class” oral therapy for CML that is expected to be late-stage-ready this summer.Analysts noted that Enliven’s current valuation does not fully reflect the size of the commercial opportunity, strategic validation, or reasonable risk-adjusted market share assumptions for the drug.Last week, Goldman Sachs raised its price target on Enliven to $59 from $41 and kept a ‘Buy’ rating on the shares, while highlighting broader competitive and industry signals, including Merck's (MRK) recent acquisition of Terns Pharmaceuticals, which underscore increasing biopharma interest in the CML space and reinforce Enliven's strategic attractiveness.In March, Clear Street also termed ELVN-001 a lower-risk, high-upside asset.According to data from Koyfin, all nine analysts covering Enliven rate it ‘Buy.’ The 12-month average price target on the stock is $57, representing a potential upside of about 44% from its last closing price.<h2 class="st-heading-2">How Did ELVN Retail Traders React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-spacex-merger-ron-baron-throws-support-behind-elon-musk-potential-move/cZXXjXNReiF">Tesla-SpaceX Merger Speculation: Ron Baron Throws Support Behind Elon Musk’s Potential Move</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil

Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm. 

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Rising bond yields and geopolitical tensions in the Middle East are causing significant market anxiety and structural price swings.

Small-cap stocks face intense selling pressure and relative weakness as liquidity concerns and rising borrowing costs rattle the sector.

Traders are closely monitoring negative gamma and dealer hedging mechanics as a potential driver for sudden, accelerated index moves.

Current Price	$277.60
Prev Close	$284.45
Open	$280.30
Dividend Yield	N/A
50-Day Moving Average	$263.83
Beta	N/A
Avg. Volume	29.42M
PE Ratio	N/A

52-Week High	$287.58
52-Week Low	$199.65
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF